CClinicalTrials.gg
CompletedNCT03733028Updated Jul 22, 2025Results posted

Mobile Intervention for Veterans With PTSD and Anger

An interventional study of Mobile Intervention for Reducing Anger (MIRA) and Mindfulness Intervention in Posttraumatic Stress Disorder and Anger, sponsored by VA Office of Research and Development. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2025-07-22.

Sponsored by VA Office of Research and Development · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Sex
All
01

Study summary

Anger is the mostly commonly reported reintegration concern among combat Veterans, especially those with PTSD. Problematic anger is associated with significant functional impairment. In the current project, the investigators will pilot-test a newly developed mobile app, entitled Mobile Intervention for Reducing Anger (MIRA), among Veterans with PTSD and problematic anger. The project will compare the MIRA app to a contact control condition. The investigators hypothesize that Veterans with PTSD and problematic anger will find the MIRA app acceptable and will be willing to use it to reduce their anger difficulties and improve psychosocial and occupational functioning.

Read the detailed description

Anger is the mostly commonly reported reintegration concern among combat Veterans, especially those with PTSD. Problematic anger is associated with significant functional impairment. One of the mechanisms associated with problematic anger and aggression is hostile interpretation bias, i.e., a tendency to interpret ambiguous interpersonal situations as hostile. The investigator has previously developed and piloted a computer-based interpretation bias modification intervention that successfully reduces both hostile interpretation bias and anger outcomes. In the current project, the investigators will pilot-test a mobile application version of the existing computer-based intervention, entitled Mobile Intervention for Reducing Anger (MIRA), among Veterans with PTSD and problematic anger. The project will compare the MIRA app to a contact control condition to evaluate the feasibility of recruitment, randomization, and retention procedures. The investigators will also utilize psychophysiological and electronic diary monitoring to determine whether this assessment could be used as an outcome or mechanistic variable in a subsequent randomized clinical trial application focused on evaluating the efficacy of the MIRA intervention.

02

Conditions studied

  • Posttraumatic Stress Disorder
  • Anger

Keywords

  • anger
  • posttraumatic stress disorder
  • hostile interpretation bias
  • mHealth
03

In context

Stress Disorders, Post-Traumatic

2,239 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 554 are open to participants now.

This study's enrollment of 30 is below the median of 70 across 1,858 interventional studies indexed under Stress Disorders, Post-Traumatic.

Browse Stress Disorders, Post-Traumatic studies →

Lead sponsor

VA Office of Research and Development is the lead sponsor of 1,733 studies on the registry; 396 are open to participants now.

Of its 206 completed or terminated interventional studies of FDA-regulated products, 180 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Veterans diagnosed with PTSD, established via the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)
  • Reporting a score of 12 on the 5-item Dimensions of Anger Reactions Scale
  • Able to read at least 6th grade level material

Exclusion criteria

Exclusion Criteria:

  • Expect to be unstable on their medication regimen during the study
  • Currently in a period of active psychosis or mania
  • Exhibit current prominent suicidal or homicidal ideation requiring immediate intervention
  • Receiving (or plan to receive) other anger management psychotherapy or trauma-focused therapy for PTSD (i.e., prolonged exposure, cognitive processing therapy during the course of the study
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Mobile Intervention for Reducing Anger (MIRA)

    Participants in this arm will be provided with a device that has the MIRA application (app) and asked to use the app for a period of 4 weeks.

    Behavioral: Mobile Intervention for Reducing Anger (MIRA)

  • Active comparator
    Mindfulness Intervention

    Participants in this arm will be provided with a device that has the Mindfulness application (app) and asked to use the app for a period of 4 weeks.

    Behavioral: Mindfulness Intervention

Interventions

  • BehavioralMobile Intervention for Reducing Anger (MIRA)

    This is a mobile intervention that uses interpretation bias modification (IBM) techniques to reduce the hostile interpretation bias. Participants will be given a mobile device with the MIRA app and instructed to complete 5 treatment sessions each week for a period of 4 weeks. Each session takes approximately 10 minutes. The app also includes a Nightly Diary to track symptoms, a calendar to program session reminders, and a My Progress feature to track use and performance.

  • BehavioralMindfulness Intervention

    This is a mobile intervention that uses the Mindful Breathing and Body Scan exercises from the "Mindfulness Coach" app. These audio-guided exercises take approximately 10 minutes each. Participants will be given a mobile device with the Mindfulness app and instructed to complete 5 exercises (i.e., Body Scan or Mindful Breathing) each week for a period of 4 weeks. The app also includes a Nightly Diary to track symptoms, a calendar to program reminders, and a My Progress feature to track use and performance.

06

What researchers measure

Primary outcomes

  1. Feasibility as Measured by Percentage of Recruitment Goal Met

    Patient recruitment goal feasibility goal will be met if recruitment is 75% or greater of recruitment expectation. Recruitment expectation is 20 in each arm.

    Time frame: Through study completion (approximately 2 years)

  2. Number of Participants Lost to Attrition During Treatment

    Treatment retention feasibility goal will be met if attrition from MIRA treatment arm is no more than 25%.

    Time frame: Post-treatment assessment visit (approximately one month after enrollment)

  3. Number of Participants Who Report Satisfaction With the MIRA App

    Patient satisfaction goal will be met if 80% or greater of participants indicate that they are either "very satisfied" or "mostly satisfied" with the MIRA app on item #7 of the Client Satisfaction Questionnaire.

    Time frame: Post-treatment assessment visit (approximately one month after enrollment)

  4. Average Number of Treatment Sessions Completed by MIRA App Users

    Our App utilization goal will be met if MIRA app utilization rates are greater than 50% of expected use. Expected use is defined as 20 sessions completed, and the app utilization goal will be met if participants complete, on average, at least 10 sessions.

    Time frame: Post-treatment assessment visit (approximately one month after enrollment)

07

Results

Posted Jul 5, 2024

Participant flow

Participant flow — Overall Study
MilestoneMobile Intervention for Reducing Anger (MIRA)Mindfulness Intervention
Started1614
Completed1614
Not completed00

Outcome measures

PrimaryFeasibility as Measured by Percentage of Recruitment Goal Met

Patient recruitment goal feasibility goal will be met if recruitment is 75% or greater of recruitment expectation. Recruitment expectation is 20 in each arm.

Time frame:
Through study completion (approximately 2 years)
Reported as:
Number · participants
Feasibility as Measured by Percentage of Recruitment Goal Met
participantsMobile Intervention for Reducing Anger (MIRA)Mindfulness Intervention
Feasibility as Measured by Percentage of Recruitment Goal Met1614
PrimaryNumber of Participants Lost to Attrition During Treatment

Treatment retention feasibility goal will be met if attrition from MIRA treatment arm is no more than 25%.

Time frame:
Post-treatment assessment visit (approximately one month after enrollment)
Reported as:
Number · participants
Number of Participants Lost to Attrition During Treatment
participantsMobile Intervention for Reducing Anger (MIRA)Mindfulness Intervention
Number of Participants Lost to Attrition During Treatment01
PrimaryNumber of Participants Who Report Satisfaction With the MIRA App

Patient satisfaction goal will be met if 80% or greater of participants indicate that they are either "very satisfied" or "mostly satisfied" with the MIRA app on item #7 of the Client Satisfaction Questionnaire.

Time frame:
Post-treatment assessment visit (approximately one month after enrollment)
Reported as:
Number · participants
Number of Participants Who Report Satisfaction With the MIRA App
participantsMIRA Group/Users Only
Number of Participants Who Report Satisfaction With the MIRA App14
PrimaryAverage Number of Treatment Sessions Completed by MIRA App Users

Our App utilization goal will be met if MIRA app utilization rates are greater than 50% of expected use. Expected use is defined as 20 sessions completed, and the app utilization goal will be met if participants complete, on average, at least 10 sessions.

Time frame:
Post-treatment assessment visit (approximately one month after enrollment)
Reported as:
Mean · sessions completed
Average Number of Treatment Sessions Completed by MIRA App Users
sessions completedMIRA Group/Users Only
Average Number of Treatment Sessions Completed by MIRA App Users17.13 ± 8.79

Adverse events

Collected over Adverse events were collected for approximately 17 weeks, from baseline to the 3-month follow-up visit.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Mobile Intervention for Reducing Anger (MIRA)0/16 (0%)0/16 (0%)2/16 (12.5%)
Mindfulness Intervention0/14 (0%)0/14 (0%)4/14 (28.6%)
Most frequent other events
Most frequent other events
EventMobile Intervention for Reducing Anger (MIRA)Mindfulness Intervention
frustration/discomfort with using the mobile appGeneral disorders1/163/14
Distress upon completing interview about posttraumatic stress disorder symptomsPsychiatric disorders1/161/14

Baseline characteristics

Age, Continuous
Age, Continuous(years)Mobile Intervention for Reducing Anger (MIRA)Mindfulness InterventionTotal
Mean51.56 ± 12.8259.29 ± 10.7654.53 ± 11.91
Sex: Female, Male
Sex: Female, Male(Participants)Mobile Intervention for Reducing Anger (MIRA)Mindfulness InterventionTotal
Female235
Male141125
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Mobile Intervention for Reducing Anger (MIRA)Mindfulness InterventionTotal
Hispanic or Latino101
Not Hispanic or Latino151429
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Mobile Intervention for Reducing Anger (MIRA)Mindfulness InterventionTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American12719
White257
More than one race101
Unknown or Not Reported123
Region of Enrollment
Region of Enrollment(Participants)Mobile Intervention for Reducing Anger (MIRA)Mindfulness InterventionTotal
United States161430
08

Study locations

1 site
  • Durham VA Medical Center, Durham, NC
    Durham, North Carolina 27705-3875, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Jul 28, 2022
  • Informed consent form · Aug 9, 2022

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03733028
Lead sponsor
VA Office of Research and Development
Responsible party
Sponsor
First posted
Nov 7, 2018
Start date
Mar 15, 2021
Primary completion
Apr 18, 2023
Completion
Jun 15, 2023
Results posted
Jul 5, 2024
Last update
Jul 22, 2025

Study contacts

Kirsten H Dillon, PhD
principal investigator · Durham VA Medical Center, Durham, NC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion